Aytu BioPharmavsJohnson & Johnson

AYTU and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

Aytu BioPharma (AYTU) has a market value of $51M and Johnson & Johnson (JNJ) $644B. Over the last year, with dividends, AYTU moved +31.2% and JNJ +36.5%. Dividend yield: AYTU none, JNJ 1.98%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AYTU$51M

    JNJ$644B

    JNJ is 12,567 times AYTU

  • Revenue, 12 months

    AYTU$59M

    JNJ$99.3B

    JNJ is 1,697 times AYTU

  • Net income, 12 months

    AYTU-$20M

    JNJ$16.1B

  • Operating margin

    AYTU-18.4%

    JNJ–

  • ROIC

    AYTU-21.6%

    JNJ12.4%

    34.0 points apart

  • P/E

    AYTU–

    JNJ40.0

  • Dividend yield

    AYTU0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    AYTU-93.3%

    JNJ+89.1%

    182.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AYTU-100.0%

JNJ+89.0%

010020020222023202420252026
Returns by period
PeriodAYTUWith dividendsJNJWith dividends
1 year since November 18, 2025+31.2%Price +31.2%+36.5%Price +33.5%
3 years since November 17, 2023+15.7%+5.0% a yearPrice +15.7%+94.2%+24.8% a yearPrice +78.3%
5 years since November 18, 2021-93.3%-41.8% a yearPrice -93.3%+89.1%+13.6% a yearPrice +64.5%
10 years since November 21, 2016-100.0%-65.1% a yearPrice -100.0%+202.6%+11.7% a yearPrice +132.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AYTUAytu BioPharmaJNJJohnson & Johnson

Valuation

AYTUJNJ
Valuation
Price$2.65$267.06
Market value$51M$644B
Enterprise value (EV)–$671B
P/E–40.0
P/E, 5-year median–21.9
P/B1.67.9
EV/EBIT–37.8
Free cash flow yield7.0%3.2%

Results and growth

AYTUJNJ
Results and growth
Revenue, 12 months$59M$99.3B
Net income, 12 months-$20M$16.1B
Free cash flow, 12 months$3.6M$20.6B
Earnings per share, 12 months-$1.52$6.59
Revenue growth, year on year-13.3%6.1%
Revenue growth a year, past-2.6%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

AYTUJNJ
Margins and returns on capital
Gross margin63.3%67.6%
Operating margin-18.4%–
Net margin-34.3%16.2%
ROIC-21.6%12.4%
ROE-72.1%19.7%

Balance sheet

AYTUJNJ
Balance sheet
Cash$25M$17.2B
Total debt–$44.7B
Net debt / EBITDA–1.1
Interest cover-6.0×18.0×

Dividends and buybacks

AYTUJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AYTU or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Aytu BioPharma or Johnson & Johnson?

By market value, Johnson & Johnson ($644B) is about 12,567.4 times Aytu BioPharma ($51M), at today's prices.

How did AYTU and JNJ stock do over the last 10 years?

Since November 21, 2016, AYTU's price moved -100.0% and JNJ's +132.2%. With dividends: AYTU -100.0% (-65.1% a year), JNJ +202.6% (+11.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, AYTU or JNJ?

The dividend yield at today's price is none for Aytu BioPharma and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Aytu BioPharma or Johnson & Johnson?

Over the last twelve months, the net margin was -34.3% for Aytu BioPharma and 16.2% for Johnson & Johnson, and the operating margin -18.4% and –. Revenue was $59M and $99.3B.

Which is the better investment, Aytu BioPharma or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.